FDA EMDAC backs Janssen's SGLT2 canagliflozin; but CV concerns linger
This article was originally published in Scrip
Executive Summary
The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on 10 January backed approval of Janssen's experimental selective sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin as a treatment to improve glycemic control in patients with Type II diabetes, despite some concerns about the drug's cardiovascular (CV) and renal safety.